Bio-Rad Laboratories (BIO) Stock Forecast, Price Target & Predictions
BIO Stock Forecast
Bio-Rad Laboratories stock forecast is as follows: an average price target of $565.00 (represents a 69.33% upside from BIO’s last price of $333.66) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.
BIO Price Target
The average price target for Bio-Rad Laboratories (BIO) is $565.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $565.00 to $565.00. This represents a potential 69.33% upside from BIO's last price of $333.66.
BIO Analyst Ratings
According to 4 Wall Street analysts, Bio-Rad Laboratories's rating consensus is 'Hold'. The analyst rating breakdown for BIO stock is 0 'Strong Buy' (0.00%), 1 'Buy' (25.00%), 3 'Hold' (75.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Bio-Rad Laboratories Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 07, 2022 | - | RBC Capital | $565.00 | $399.59 | 41.39% | 69.33% |
The latest Bio-Rad Laboratories stock forecast, released on Dec 07, 2022 by RBC Capital company, set a price target of $565.00, which represents a 41.39% increase from the stock price at the time of the forecast ($399.59), and a 69.33% increase from BIO last price ($333.66).
Bio-Rad Laboratories Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $333.66 | $333.66 | $333.66 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Bio-Rad Laboratories stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bio-Rad Laboratories's last price of $333.66. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | Wells Fargo | - | Equal-Weight | Initialise |
| Jun 03, 2024 | Jefferies | - | Hold | Downgrade |
| Apr 03, 2024 | Citigroup | - | Neutral | Downgrade |
| Dec 07, 2022 | RBC Capital | - | Outperform | Initialise |
Bio-Rad Laboratories's last stock rating was published by Wells Fargo on Aug 27, 2024. The company Initialise its BIO rating from "null" to "Equal-Weight".
Bio-Rad Laboratories Financial Forecast
Bio-Rad Laboratories Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $2.67T | $632.12M | $681.11M | $676.84M | $730.29M | $680.80M | - | $700.06M | $732.77M | $747.05M | $715.93M | $726.80M | $789.84M | $647.26M | $536.88M | $571.64M | $624.43M | $560.63M |
| Avg Forecast | $744.85M | $667.43M | $687.34M | $657.27M | $729.63M | $654.67M | $667.03M | $641.54M | $696.06M | $629.19M | $645.79M | $619.09M | $685.00M | $689.50M | $697.96M | $689.96M | $742.26M | $679.94M | $682.62M | $672.63M | $730.26M | $664.57M | $646.07M | $660.98M | $686.79M | $570.57M | $517.06M | $546.85M | $641.46M | $561.40M |
| High Forecast | $761.30M | $682.18M | $702.53M | $671.80M | $745.75M | $669.14M | $681.76M | $655.71M | $711.44M | $643.09M | $660.06M | $632.77M | $685.01M | $692.76M | $713.39M | $705.21M | $758.66M | $694.97M | $682.62M | $682.49M | $740.97M | $674.32M | $655.55M | $670.67M | $696.86M | $578.94M | $524.64M | $554.87M | $650.87M | $569.63M |
| Low Forecast | $733.34M | $657.12M | $676.72M | $647.12M | $718.35M | $644.55M | $656.72M | $631.62M | $685.30M | $629.18M | $635.81M | $609.53M | $684.99M | $683.17M | $687.18M | $679.30M | $730.79M | $669.43M | $682.62M | $662.69M | $719.47M | $654.75M | $636.52M | $651.21M | $676.64M | $562.14M | $509.41M | $538.77M | $631.98M | $553.10M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3896.77% | 0.92% | 0.98% | 0.98% | 0.98% | 1.00% | - | 1.04% | 1.00% | 1.12% | 1.11% | 1.10% | 1.15% | 1.13% | 1.04% | 1.05% | 0.97% | 1.00% |
Bio-Rad Laboratories's average Quarter revenue forecast for Mar 24 based on 1 analysts is $619.09M, with a low forecast of $609.53M, and a high forecast of $632.77M. BIO's average Quarter revenue forecast represents a -99.98% decrease compared to the company's last Quarter revenue of $2.67T (Dec 23).
Bio-Rad Laboratories EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-373.97B | $90.95M | $89.62M | $147.93M | $160.83M | $128.58M | - | $208.03M | $-2.00B | $5.06B | $1.19B | $1.33B | $1.12B | $1.72B | $1.29B | $937.99M | $708.79M | $-284.69M |
| Avg Forecast | $159.29M | $142.73M | $146.99M | $140.56M | $156.03M | $140.00M | $142.65M | $137.19M | $148.85M | $134.55M | $138.10M | $-1.70B | $146.49M | $147.45M | $149.26M | $-1.54B | $158.73M | $145.41M | $145.98M | $-1.40B | $-1.77B | $142.12M | $138.16M | $141.35M | $146.87M | $122.02M | $110.57M | $116.95M | $137.18M | $-244.31M |
| High Forecast | $162.81M | $145.89M | $150.24M | $143.67M | $159.48M | $143.10M | $145.80M | $140.23M | $152.14M | $137.53M | $141.16M | $-1.36B | $146.49M | $148.15M | $152.56M | $-1.23B | $162.24M | $148.62M | $145.98M | $-1.12B | $-1.41B | $144.20M | $140.19M | $143.43M | $149.03M | $123.81M | $112.20M | $118.66M | $139.19M | $-195.45M |
| Low Forecast | $156.83M | $140.53M | $144.72M | $138.39M | $153.62M | $137.84M | $140.44M | $135.07M | $146.55M | $134.55M | $135.97M | $-2.04B | $146.49M | $146.10M | $146.95M | $-1.85B | $156.28M | $143.16M | $145.98M | $-1.68B | $-2.12B | $140.02M | $136.12M | $139.26M | $144.70M | $120.21M | $108.94M | $115.22M | $135.15M | $-293.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -2552.92% | 0.62% | 0.60% | -0.10% | 1.01% | 0.88% | - | -0.15% | 1.13% | 35.58% | 8.62% | 9.41% | 7.62% | 14.13% | 11.63% | 8.02% | 5.17% | 1.17% |
2 analysts predict BIO's average Quarter EBITDA for Dec 23 to be $146.49M, with a high of $146.49M and a low of $146.49M. This is 61.07% upper than Bio-Rad Laboratories's previous annual EBITDA (Sep 23) of $90.95M.
Bio-Rad Laboratories Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-636.34B | $106.26M | $-1.16B | $68.96M | $827.73M | $-164.23M | - | $-3.37B | $-1.57B | $3.93B | $914.11M | $977.41M | $839.10M | $1.31B | $966.43M | $685.91M | $553.49M | $-258.82M |
| Avg Forecast | $99.57M | $74.54M | $106.91M | $79.24M | $88.00M | $70.63M | $84.02M | $76.56M | $78.13M | $40.31M | $57.20M | $-2.45B | $80.02M | $79.00M | $76.07M | $-2.23B | $97.92M | $2.28B | $79.87M | $-2.03B | $-1.39B | $2.07B | $628.67M | $955.04M | $658.57M | $1.04B | $657.49M | $537.37M | $580.71M | $-222.10M |
| High Forecast | $102.43M | $76.69M | $109.98M | $81.51M | $90.53M | $72.66M | $86.43M | $78.76M | $80.37M | $41.47M | $58.85M | $-1.96B | $82.32M | $82.98M | $78.26M | $-1.78B | $100.73M | $2.73B | $79.87M | $-1.62B | $-1.11B | $2.49B | $754.40M | $1.15B | $790.28M | $1.24B | $788.99M | $644.84M | $696.85M | $-177.68M |
| Low Forecast | $97.57M | $73.05M | $104.76M | $77.64M | $86.24M | $69.21M | $82.33M | $75.02M | $76.56M | $40.12M | $56.05M | $-2.94B | $79.75M | $74.45M | $74.54M | $-2.68B | $95.95M | $1.82B | $79.87M | $-2.43B | $-1.66B | $1.66B | $502.93M | $764.04M | $526.85M | $828.74M | $525.99M | $429.90M | $464.57M | $-266.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -7952.12% | 1.35% | -15.28% | -0.03% | 8.45% | -0.07% | - | 1.66% | 1.13% | 1.90% | 1.45% | 1.02% | 1.27% | 1.27% | 1.47% | 1.28% | 0.95% | 1.17% |
Bio-Rad Laboratories's average Quarter net income forecast for Dec 23 is $80.02M, with a range of $79.75M to $82.32M. BIO's average Quarter net income forecast represents a -24.69% decrease compared to the company's last Quarter net income of $106.26M (Sep 23).
Bio-Rad Laboratories SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $841.09B | $201.20M | $207.82M | $225.55M | $212.23M | $211.05M | - | $197.59M | $224.15M | $216.15M | $213.43M | $225.85M | $219.15M | $198.16M | $189.26M | $193.69M | $214.16M | $201.62M |
| Avg Forecast | $234.58M | $210.20M | $216.47M | $207.00M | $229.78M | $206.18M | $210.07M | $202.04M | $219.21M | $198.15M | $203.38M | $143.88M | $215.73M | $217.15M | $219.81M | $130.80M | $233.76M | $125.41M | $214.98M | $118.91M | $197.59M | $114.01M | $146.78M | $220.68M | $172.00M | $156.13M | $128.76M | $151.75M | $224.70M | $173.02M |
| High Forecast | $239.76M | $214.84M | $221.25M | $211.57M | $234.86M | $210.73M | $214.71M | $206.51M | $224.06M | $202.53M | $207.88M | $172.65M | $215.73M | $218.18M | $224.67M | $156.95M | $238.93M | $150.49M | $214.98M | $142.69M | $237.11M | $136.81M | $176.14M | $264.82M | $206.40M | $187.36M | $154.51M | $182.10M | $269.64M | $207.63M |
| Low Forecast | $230.95M | $206.95M | $213.12M | $203.80M | $226.23M | $202.99M | $206.82M | $198.92M | $215.83M | $198.15M | $200.24M | $115.10M | $215.73M | $215.16M | $216.42M | $104.64M | $230.15M | $100.33M | $214.98M | $95.12M | $158.07M | $91.21M | $117.42M | $176.55M | $137.60M | $124.90M | $103.01M | $121.40M | $179.76M | $138.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3898.81% | 0.93% | 0.95% | 1.72% | 0.91% | 1.68% | - | 1.66% | 1.13% | 1.90% | 1.45% | 1.02% | 1.27% | 1.27% | 1.47% | 1.28% | 0.95% | 1.17% |
Bio-Rad Laboratories's average Quarter SG&A projection for Mar 24 is $143.88M, based on 1 Wall Street analysts, with a range of $115.10M to $172.65M. The forecast indicates a -99.98% fall compared to BIO last annual SG&A of $841.09B (Dec 23).
Bio-Rad Laboratories EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-21.79 | $3.65 | $-39.59 | $2.33 | $27.89 | $-5.52 | - | $-112.57 | $-52.59 | $131.75 | $30.71 | $32.77 | $28.13 | $44.24 | $32.59 | $22.97 | $18.50 | $-8.68 |
| Avg Forecast | $3.51 | $2.63 | $3.77 | $2.79 | $3.10 | $2.49 | $2.96 | $2.70 | $2.75 | $1.42 | $2.01 | $2.15 | $2.82 | $2.78 | $2.68 | $3.54 | $3.45 | $2.78 | $2.80 | $3.37 | $2.85 | $2.44 | $2.66 | $2.99 | $3.29 | $1.80 | $1.22 | $1.57 | $2.45 | $1.41 |
| High Forecast | $3.61 | $2.70 | $3.87 | $2.87 | $3.19 | $2.56 | $3.04 | $2.77 | $2.83 | $1.46 | $2.07 | $2.21 | $2.90 | $2.92 | $2.76 | $3.64 | $3.55 | $2.86 | $2.80 | $3.43 | $2.90 | $2.48 | $2.72 | $3.05 | $3.36 | $1.84 | $1.25 | $1.59 | $2.49 | $1.43 |
| Low Forecast | $3.44 | $2.57 | $3.69 | $2.73 | $3.04 | $2.44 | $2.90 | $2.64 | $2.70 | $1.41 | $1.97 | $2.10 | $2.81 | $2.62 | $2.63 | $3.47 | $3.38 | $2.73 | $2.80 | $3.30 | $2.80 | $2.39 | $2.61 | $2.94 | $3.23 | $1.77 | $1.20 | $1.53 | $2.40 | $1.38 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -7.73% | 1.31% | -14.78% | 0.66% | 8.09% | -1.98% | - | -33.41% | -18.45% | 54.06% | 11.53% | 10.94% | 8.54% | 24.55% | 26.64% | 14.68% | 7.57% | -6.18% |
According to 2 Wall Street analysts, Bio-Rad Laboratories's projected average Quarter EPS for Dec 23 is $2.82, with a low estimate of $2.81 and a high estimate of $2.90. This represents a -22.79% decrease compared to BIO previous annual EPS of $3.65 (Sep 23).
Bio-Rad Laboratories Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NVCR | NovoCure | $18.02 | $67.92 | 276.91% | Hold |
| TNDM | Tandem Diabetes Care | $43.06 | $84.44 | 96.10% | Buy |
| BIO | Bio-Rad Laboratories | $333.66 | $565.00 | 69.33% | Hold |
| NARI | Inari Medical | $44.10 | $70.33 | 59.48% | Buy |
| CNMD | CONMED | $74.80 | $101.00 | 35.03% | Buy |
| ZBH | Zimmer Biomet | $106.24 | $137.17 | 29.11% | Hold |
| DXCM | DexCom | $68.94 | $81.86 | 18.74% | Buy |
| PEN | Penumbra | $187.06 | $220.80 | 18.04% | Hold |
| PODD | Insulet | $235.54 | $272.27 | 15.59% | Buy |
| INSP | Inspire Medical Systems | $206.70 | $237.80 | 15.05% | Buy |
| GMED | Globus Medical | $69.34 | $79.54 | 14.71% | Buy |
| BRKR | Bruker | $65.03 | $71.67 | 10.21% | Buy |
| ITGR | Integer | $126.12 | $131.00 | 3.87% | Buy |
| STE | STERIS | $241.68 | $245.00 | 1.37% | Buy |
| GKOS | Glaukos | $121.58 | $101.56 | -16.47% | Buy |
| SWAV | ShockWave Medical | $334.75 | $258.17 | -22.88% | Hold |
BIO Forecast FAQ
Is Bio-Rad Laboratories a good buy?
No, according to 4 Wall Street analysts, Bio-Rad Laboratories (BIO) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 25.00% of BIO's total ratings.
What is BIO's price target?
Bio-Rad Laboratories (BIO) average price target is $565 with a range of $565 to $565, implying a 69.33% from its last price of $333.66. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bio-Rad Laboratories stock go up soon?
According to Wall Street analysts' prediction for BIO stock, the company can go up by 69.33% (from the last price of $333.66 to the average price target of $565), up by 69.33% based on the highest stock price target, and up by 69.33% based on the lowest stock price target.
Can Bio-Rad Laboratories stock reach $500?
BIO's average twelve months analyst stock price target of $565 supports the claim that Bio-Rad Laboratories can reach $500 in the near future.
What are Bio-Rad Laboratories's analysts' financial forecasts?
Bio-Rad Laboratories's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.69B (high $2.75B, low $2.65B), average EBITDA is $575.88M (high $588.6M, low $566.98M), average net income is $319.21M (high $328.38M, low $312.8M), average SG&A $848.08M (high $866.82M, low $834.97M), and average EPS is $11.24 (high $11.56, low $11.02). BIO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.76B (high $2.82B, low $2.71B), average EBITDA is $589.57M (high $602.6M, low $580.46M), average net income is $360.26M (high $370.61M, low $353.02M), average SG&A $868.24M (high $887.43M, low $854.83M), and average EPS is $12.69 (high $13.05, low $12.43).
Did the BIO's actual financial results beat the analysts' financial forecasts?
Based on Bio-Rad Laboratories's last annual report (Dec 2023), the company's revenue was $2.67T, beating the average analysts forecast of $2.76B by 96599.93%. Apple's EBITDA was $337.8B, missing the average prediction of $-1.101B by -30793.59%. The company's net income was $-637B, beating the average estimation of $-1.995B by 31839.72%. Apple's SG&A was $841.72B, beating the average forecast of $783.49M by 107332.97%. Lastly, the company's EPS was $-21.82, missing the average prediction of $11.82 by -284.58%. In terms of the last quarterly report (Dec 2023), Bio-Rad Laboratories's revenue was $2.67T, beating the average analysts' forecast of $685M by 389576.55%. The company's EBITDA was $-374B, missing the average prediction of $146.49M by -255391.68%. Bio-Rad Laboratories's net income was $-636B, missing the average estimation of $80.02M by -795311.59%. The company's SG&A was $841.09B, beating the average forecast of $215.73M by 389781.31%. Lastly, the company's EPS was $-21.79, missing the average prediction of $2.82 by -873.21%